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Abstract
Background: We have recently shown that curcumin (a diferuloylmethane, the yellow pigment in
turmeric) enhances apoptosis-inducing potential of TRAIL in prostate cancer PC-3 cells, and
sensitizes TRAIL-resistant LNCaP cells in vitro through multiple mechanisms. The objectives of this
study were to investigate the molecular mechanisms by which curcumin sensitized TRAIL-resistant
LNCaP xenografts in vivo.
Methods: Prostate cancer TRAIL-resistant LNCaP cells were implanted in Balb c nude mice to
examine the effects of curcumin and/or TRAIL on tumor growth and genes related to apoptosis,
metastasis and angiogenesis.
Results: Curcumin inhibited growth of LNCaP xenografts in nude mice by inducing apoptosis
(TUNEL staining) and inhibiting proliferation (PCNA and Ki67 staining), and sensitized these
tumors to undergo apoptosis by TRAIL. In xenogrfated tumors, curcumin upregulated the
expression of TRAIL-R1/DR4, TRAIL-R2/DR5, Bax, Bak, p21/WAF1, and p27/KIP1, and inhibited the
activation of NFκB and its gene products such as cyclin D1, VEGF, uPA, MMP-2, MMP-9, Bcl-2 and
Bcl-XL. The regulation of death receptors and members of Bcl-2 family, and inactivation of NFκB
may sensitize TRAIL-resistant LNCaP xenografts. Curcumin also inhibited number of blood vessels
in tumors, and circulating endothelial growth factor receptor 2-positive endothelial cells in mice.
Conclusion: The ability of curcumin to inhibit tumor growth, metastasis and angiogenesis, and
enhance the therapeutic potential of TRAIL suggests that curcumin alone or in combination with
TRAIL can be used for prostate cancer prevention and/or therapy.
Introduction
The process of malignant transformation involves the
sequential acquisition of a number of genetic and epige-
netic alterations as a result of increasing genomic instabil-
ity caused by defects in checkpoint controls [1,2]. These
alterations allow cancer cells to acquire the capabilities to
become self-sufficient in mitogenic signals, deregulate the
control of cell cycle, escape from apoptosis, and obtain
unlimited replication potential [3-5]. Within a growing
tumor mass, the genetic changes during tumor progres-
sion also enable cancer cells to gain the ability to induce
angiogenesis, invade neighboring tissues, and metastasize
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to distinct organs [6]. The new chemopreventive agents or
therapeutic strategies that inhibit angiogenesis, metastasis
and invasion can be considered for future clinical devel-
opment.
Epidemiological data have demonstrated that curcumin is
safe, non-toxic, and has long lasting beneficial effects on
human health. Curcumin [1,7-bis(4-hydroxy-3-methoxy-
phenyl)-1,6-hepatadiene-3,5-dione; diferulolylmeth-
ane], a major constituent of the yellow spice turmeric, is
derived from the rhizomes of Curcuma spp. [7]. It pos-
sesses antitumor, anti-inflammatory and anti-oxidant
properties [7,8]. In addition, curcumin has been shown to
inhibit tumor metastasis, invasion and angiogenesis [9-
12]. We have recently shown that Bax and Bak genes com-
pletely inhibited curcumin-induced apoptosis in Bax-/-
and Bax -/- mouse embryonic fibroblasts [13], and curcu-
min induced apoptosis in prostate cancer cells by inhibit-
ing Akt activity upstream of mitochondria [14]. These data
suggest that curcumin regulates multiple signaling path-
ways and possesses several therapeutic benefits.
Nuclear factor (NFκB) is a dimeric DNA binding protein
consisting of members of the NFκB/Rel family [15]. Its
expression is ubiquitous in mammalian cells. Normally,
NFκB resides in the cytoplasm in an inactive form in asso-
ciation with inhibitory proteins. These inhibitory pro-
teins, which belong to a family of proteins named
inhibitor of NFκB [15], prevent NFκB nuclear transloca-
tion by masking the NFκB nuclear localization signal and
thus, inhibit NFκB DNA binding and transactivational
function [15,16]. Various stimuli activate a large number
of distinct signaling pathways that eventually result in the
phosphorylation of inhibitor of NFκB and its subsequent
degradation by the proteasome or its dissociation from
NFκB without additional degradation [15-17]. The
released NFκB then translocates to the nucleus and binds
to κB DNA motifs to initiate gene transcription. The puta-
tive target genes of NFκB are involved in immune and
inflammatory responses, and in the control of cell prolif-
eration, apoptosis, metastasis and angiogenesis [15,16].
Tumor cells usually express high levels of constitutively
active NFκB [16,18]. Furthermore, curcumin inhibited
NFκB activity in cancer cells [9,19] and sensitized cancer
cells to chemotherapy and radiotherapy [20-25].
TNF-related apoptosis-inducing ligand (TRAIL) binds to
TRAIL-R1/DR4 and TRAIL-R2/DR5. TRAIL induces apop-
tosis in cancer cells of various origins [26-30]. Data on
experimental animals and primates led us to believe that
TRAIL has great promise as a selective anticancer agent
[27,28,31]. We have recently demonstrated that TRAIL
induces apoptosis in several prostate cancer cells lines, but
it was ineffective in inducing apoptosis in LNCaP cells
[27,28,32]. Furthermore, curcumin sensitizes TRAIL-
resistant prostate cancer cells to growth inhibition by
TRAIL in vitro [33-35]. However, the ability of curcumin to
sensitize TRAIL-resistant prostate cancer cells in vivo has
not yet been demonstrated.
The purpose of our studies was to investigate the molecu-
lar mechanisms by which curcumin sensitized TRAIL-
resistant prostate cancer cells in vivo. Our results indicated
that curcumin inhibited growth, metastasis, and angio-
genesis of TRAIL-resistant LNCaP xenografts in nude mice
through regulation of NFκB and its gene products, and
sensitized these xenografts to TRAIL treatment. Thus, cur-
cumin can be used alone or combined with TRAIL for
prostate cancer prevention and/or therapy.
Results
Curcumin sensitizes TRAIL-resistant tumor cells in vivo
We have recently shown that curcumin sensitizes TRAIL-
resistant prostate cancer LNCaP cells in vitro [35]. There-
fore in the present study, we examined the ability of cur-
cumin to sensitize TRAIL-resistant LNCaP cells in vivo.
LNCaP cells were xenografted in Balb c nude mice. After
tumor formation, these mice were treated with curcumin,
TRAIL, or curcumin plus TRAIL for 6 weeks to examine
their effects on tumor growth and markers of prolifera-
tion, apoptosis, metastasis, invasion and angiogenesis.
While TRAIL was ineffective in inhibiting the tumor
growth, curcumin inhibited the growth of LNCaP
xenografts in nude mice (Fig. 1A). Interestingly, curcumin
sensitized TRAIL-resistant xenografts in nude mice, which
was evident in reduction in tumor volume starting from
week 2.
Since tumor growth is determined by the balance of cell
proliferation and apoptosis, mechanisms that promote
cell survival or prevent apoptosis of cancer cells would
favor the establishment of tumor colonies. To test this, we
examined the extent of cellular apoptosis in those tumors.
Examination of tumor tissues by TUNEL assay revealed
that curcumin alone induced apoptosis (Fig. 1B and 1C).
A very few apoptotic cells were found in the highly vascu-
larized tumors derived from control mice. TRAIL treat-
ment of mice had no significant effect on apoptosis
compared to control mice. On the other hand, treatment
of mice with a combination of curcumin and TRAIL signif-
icantly showed more apoptosis than that of mice treated
with curcumin alone. Immunohistochemical studies also
demonstrated that curcumin inhibited cell proliferation
(PCNA and Ki67 staining) in xenogrfated tumors (Fig. 1B
and 1C). TRAIL had no effect on tumor cell proliferation
because the staining of PCNA and Ki67 was not affected.
The combination of curcumin plus TRAIL demonstrated
slightly less tumor cell proliferation than curcumin alone.
These data are in agreement with our recently published inMolecular Cancer 2008, 7:16 http://www.molecular-cancer.com/content/7/1/16
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vitro  data where curcumin sensitized TRAIL-resistant
LNCaP cells [35].
In vivo regulation of Bcl-2 family members and death 
receptors by curcumin and/or TRAIL
Since curcumin sensitized TRAIL-resistant cells in vivo, we
sought to examine the molecular mechanisms by which
curcumin sensitized TRAIL-resistant LNCaP cells. We next
examined the effects of curcumin and/or TRAIL on the
expression of Bcl-2 family members (Bax, Bak, Bcl-2, and
Bcl-XL) and death receptors (TRAIL-R1/DR4 and TRAIL-
R2/DR5) by immunohistochemistry in tumor tissues
derived from in vivo experiment (Fig. 2). Treatment of
mice with curcumin enhanced the expression of Bax, Bak,
DR4 and DR5, and inhibited the expression of antiapop-
totic Bcl-2 and Bcl-XL proteins. TRAIL has no significant
effect on the expression of Bak, Bax, Bcl-2, Bcl-XL, DR4
and DR5. On the other hand, treatment of mice with a
combination of curcumin and TRAIL significantly showed
more expression of Bax, Bak, DR4 and DR5, and less
expression of Bcl-2 and Bcl-XL proteins than that of mice
treated with curcumin alone or TRAIL alone.
We confirmed the immunohistochemistry data by exam-
ining the expression of these proteins by the Western blot
analysis (Fig. 3). TRAIL has no effect on the expression of
Bcl-2 family members (Bax, Bak, Bcl-2, and Bcl-XL) and
death receptors (DR4 and DR5). By comparison, curcu-
Curcumin sensitizes TRAIL-resistant LNCaP xenografts Figure 1
Curcumin sensitizes TRAIL-resistant LNCaP xenografts. (A), LNCaP cells were injected into the right flanks of Balb c nude 
mice. After tumor formation (about 100 mm3), mice were treated with saline, curcumin (30 mg/kg, three days per week), 
TRAIL (15 mg/kg, four times during first three weeks) or curcumin and TRAIL. Tumor volume was calculated weekly. Data 
represent mean ± SE. (B), Effects of curcumin and/TRAIL on apoptosis (TUNEL staining) and cell proliferation (PCNA and Ki67 
staining). Immunohistochemistry was performed to measure apoptosis (TUNEL assay), and expression of PCNA and Ki67 in 
tumor tissues derived from control and treated mice on week 6. (C), Quantification of TUNEL, PCNA and Ki67 positive 
tumor cells. Tumor slides of different treatment groups were visualized under microscope, and TUNEL, PCNA and Ki67 posi-
tive cells were quantified. Data represent mean ± SE. a1, a2; b1, b2 and c1, c2 are significantly different from their respective 
controls or TRAIL treated group (P < 0.05).
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min induced the expression of Bak, Bax, DR4 and DR5,
and inhibited the expression of Bcl-2 and Bcl-XL. These
data are in agreement with immunohistochemistry data
where the expression of proapoptotic Bak, Bax, DR4 and
DR5 proteins were induced and the expression of antiap-
optotic Bcl-2 and Bcl-XL proteins were inhibited.
In vivo regulation of cell cycle inhibitors (p21/WAF1/CIP1 and 
p27/KIP1) and cyclin D1 by curcumin and/or TRAIL
Since curcumin caused growth arrest by inducing expres-
sion of cell cycle inhibitors p21/WAF1/CIP1 and p27/KIP1 in
vitro, we sought to validate this phenomenon in vivo in
xenografted tumors. Treatment of mice with curcumin
resulted in the induction of cell cycle inhibitors p21/WAF1/
CIP1 and p27/KIP1 and inhibition of cyclin D1 (Fig. 4A). By
comparison, TRAIL had no effect on the expression of
p21, p27 and cyclin D1 compared to control group. How-
ever, the combination of curcumin and TRAIL showed
upregulation of p21 and p27, and inhibition of cyclin D1
compared to that of curcumin or TRAIL treated group. We
next confirmed the immunohistochemistry data by exam-
ining the expression of these proteins by the Western blot
analysis (Fig. 4B). TRAIL has no significant effect on the
expression of p21, p27 and cyclin D1. By comparison, cur-
cumin induced the expression of p21 and p27, and inhib-
ited the expression of cyclin D1. These mice data are in
agreement with in vitro data where curcumin upregulated
the expression of p21 and p27, and inhibited the expres-
sion of cyclin D1 [35].
In vivo regulation of NFκB, Cox-2 and IL-8 by curcumin 
and/or TRAIL
The NFκB family of transcription factors has been shown
to be constitutively activated in cancer cells and thus reg-
ulates genes involved in cell proliferation, apoptosis,
metastasis and angiogenesis [36]. Since NFκB, Cox-2 and
IL-8 play major role in cancer cell proliferation, and
immune response, we sought to examine the effects of
curcumin and/or TRAIL on the expression of these pro-
teins by immunohistochemistry in tumor tissues derived
Immunohistochemical examination of Bcl-2 family members and death receptors Figure 2
Immunohistochemical examination of Bcl-2 family members and death receptors. Immunohistochemistry was performed to 
measure the expression of Bak, Bax, Bcl-2, Bcl-XL, TRAIL-R1/DR4 and TRAIL-R2/DR5 in tumor tissues derived from control 
and/or treated mice on week 6.
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from xenograft experiment (Fig. 5A). While TRAIL was
ineffective, treatment of xenogrfated mice with curcumin
resulted in inhibition of NFκB activation (as measured by
phospho-p65 antibody), and cox-2 and IL-8 expression
than control group. Furthermore, the combination of cur-
cumin and TRAIL was more effective than curcumin alone
in inhibiting NFκB activation and expression of cox-2 and
IL-8.
We next confirmed the immunohistochemistry data by
examining the expression of these proteins by the Western
blot analysis (Fig. 5B). TRAIL has no significant effect on
the phosphorylation of p-p65, and expression of cox-2
and IL-8. By comparison, curcumin inhibited the phos-
phorylation of p-p65, and expression of Cox-2 and IL-8.
These data suggest that curcumin can inhibit NFκB activa-
tion and its gene products such as Cox-2 and IL-8.
Since curcumin inhibited the phosphorylation of p65
subunit of NFκB, we next measured the NFκB-DNA bind-
ing activity in tumor tissues derived from control, TRAIL,
curcumin, and curcumin plus TRAIL treated groups.
Nuclear extracts were prepared from tumor tissues derived
from different treatment groups, and NFκB-DNA binding
activity was measured by gelshift assay (Fig. 5C). TRAIL
had no effect on NFκB-DNA binding activity compared to
that of untreated mice. By comparison, curcumin inhib-
ited NFκB-DNA binding activity by 53%. Interestingly, the
combination of curcumin and TRAIL had more inhibitory
effects on NFκB-DNA binding activity than curcumin
alone. These data suggest that the inhibition of NFκB tran-
scription factor by curcumin may play a major role in
inducing sensitivity of TRAIL-resistant cells.
In vivo regulation of angiogenesis by curcumin and/or 
TRAIL
Whether regression in tumor growth by curcumin was due
to inhibition of angiogenesis, we analyzed the markers of
angiogenesis by immunohistochemistry in tumor sam-
ples. Examination of tumor tissues by immunohisto-
chemistry showed that control mice had increased VEGF-
positive endothelial cells compared to curcumin treated
mice (Fig. 6A). TRAIL had no effect on VEGF staining. The
combination of curcumin and TRAIL showed significantly
less VEGF staining than that noted in tumors from mice
treated with either agent alone.
We next examined the effects of curcumin and/or TRAIL
treatment on number of blood vessels in tumor tissues by
utilizing three different approaches (Fig. 6B). Blood ves-
sels were examined by staining the tumor tissues by H&E,
anti-CD31 antibody, and anti-vWF antibody. TRAIL treat-
ment had no effect on number of blood vessels. By com-
parison, treatment of mice with curcumin caused an
inhibition in number of blood vessels. The combination
of curcumin with TRAIL further inhibited the number of
blood vessels.
Several laboratories, including ours, have demonstrated
that numbers of circulating vascular endothelial growth
factor receptor 2 (VEGF-R2)-positive endothelial cells cor-
relate directly with increase in tumor angiogenesis and
can serve as in vivo indicators of tumor angiogenesis
[27,37,38]. As expected, control mice had increased circu-
lating VEGF-R2-positive endothelial cells compared to
curcumin treated mice (Fig. 6C). Curcumin plus TRAIL-
Western blot analysis of Bcl-2 family members and death  receptors Figure 3
Western blot analysis of Bcl-2 family members and death 
receptors. Protein expression of Bak, Bax, Bcl-2, Bcl-XL, 
TRAIL-R1/DR4, TRAIL-R2/DR5 and β-actin in tumor tissues 
derived from control and/or treated on week 6 was meas-
ured by the Western blot analysis.
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treated group had more inhibitory effects on VEGFR2-
positive cells than that of curcumin or TRAIL treated
group. Thus, these data strongly demonstrate that curcu-
min can inhibit tumor growth by inhibiting angiogenesis,
and may also sensitize TRAIL-resistant tumor cells in vivo.
We next confirmed the immunohistochemistry data of
VEGF expression by examining the protein levels by the
Western blot analysis (Fig. 6D). TRAIL has no significant
effect on VEGF expression. By comparison, curcumin or
curcumin plus TRAIL inhibited the expression of VEGF.
In vivo regulation of metastasis by curcumin and/or TRAIL
Elevated expression of matrix metalloproteinases (MMPs)
and uPA are associated with increased metastatic potential
in many tumor cells [39-42]. We therefore sought to
examine the effects of curcumin on MMP-2, MMP-9, and
uPA on tumor tissues derived from xenografted nude
mice. Treatment of xenogrfated mice with curcumin
resulted in inhibition of MMP-2, MMP-7, and uPA expres-
sion than those of control or TRAIL group (Fig. 7A). The
combination of curcumin and TRAIL was more effective
in inhibiting MMP-2, MMP-7, and uPA expression than
single agent alone. We next confirmed the immunohisto-
chemistry data by examining the expression of these pro-
teins by the Western blot analysis (Fig. 7B). TRAIL has no
significant effect on the expression of MMP-2, MMP-9 and
uPA. By comparison, curcumin or curcumin plus TRAIL
inhibited the expression of MMP-2, MMP-9 or uPA. These
data suggest that curcumin can inhibit prostate cancer
progression by inhibiting metastasis.
Discussion
We have recently shown that curcumin induces apoptosis
in TRAIL-sensitive PC-3 cells, and sensitizes TRAIL-resist-
ant LNCaP cells in vitro through activation of multiple sig-
naling pathways [35]. Curcumin-induced apoptosis
engages mitochondria, which was evident by drop in
mitochondrial membrane potential and activation of cas-
pase-3 and caspase-9 in both prostate cancer PC-3 and
LNCaP cells [35]. Curcumin induced expression of proap-
optotic proteins (Bax, Bak, PUMA, Noxa and Bim), death
Effects of curcumin and/TRAIL on cell cycle inhibitors and cyclin D1 Figure 4
Effects of curcumin and/TRAIL on cell cycle inhibitors and cyclin D1. (A), Immunohistochemistry was performed to measure 
the expression of cell cycle inhibitors (p21/WAF1 and p27/KIP1) and cyclin D1 in tumor tissues derived from control and/or 
treated mice on week 6. (B), Expression of p21/WAF1, p27/KIP1, cyclin D1 and β-actin in tumor tissues derived on week 6 were 
measured by the Western blot analysis.
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receptors (TRAIL-R1/DR4 and TRAIL-R2/DR5), and
inhibited expression of antiapoptotic proteins (Bcl-2 and
Bcl-XL) and IAPs (XIAP and survivin) [35]. Since these
proteins regulate cell-intrinsic and/or cell-extrinsic path-
ways of apoptosis, and they may be responsible for sensi-
tization of TRAIL-resistant LNCaP cells. In the present
study, we have demonstrated that curcumin inhibited the
growth of LNCaP xenografts, metastasis and angiogenesis.
Although the TRAIL was ineffective alone, the combina-
tion of curcumin and TRAIL had greater effect on tumor
growth inhibition, metastasis and angiogenesis than cur-
cumin.
In vitro curcumin downregulated the expression of Bcl-2,
and Bcl-XL and upregulated the expression of p53, Bax,
Bak, PUMA, Noxa, and Bim at mRNA and protein levels
in prostate cancer cells [14]. We have also demonstrated
that curcumin upregulated the expression, phosphoryla-
tion, and acetylation of p53 in androgen-dependent
LNCaP cells [14]. The ability of curcumin to regulate gene
transcription was also evident as it caused acetylation of
histone H3 and H4 in LNCaP cells [14]. Furthermore,
treatment of LNCaP cells with curcumin resulted in trans-
location of Bax and p53 to mitochondria, production of
reactive oxygen species, drop in mitochondrial membrane
potential, release of mitochondrial proteins (cytochrome
c, Smac/DIABLO and Omi/HtrA2), and activation of cas-
pase-3 leading to apoptosis [14]. Furthermore, deletion of
Bax and Bak genes completely inhibited curcumin-
induced cytochrome c and Smac/DIABLO release in
mouse embryonic fibroblasts [13]. In the present study,
tumor tissues derived from curcumin treated mice showed
that curcumin inhibited the exprerssion of Bcl-2 and Bcl-
XL, and induced the expression of Bax and Bak. The com-
binatioin of curcumin and TRAIL was more effective in
regulating Bcl-2 family members than single agent alone.
Effects of curcumin and/TRAIL on markers of phospho-p65NFκB, Cox-2, and IL-8 Figure 5
Effects of curcumin and/TRAIL on markers of phospho-p65NFκB, Cox-2, and IL-8. (A), Immunohistochemistry was performed 
to measure the expression of phospho-p65NFκB, Cox-2 and IL-8 in tumor tissues derived from control and/or treated mice 
on week 6. (B), Expression of phospho-p65NFκB, Cox-2, IL-8 and β-actin in tumor tissues derived on week 6 were measured 
by the Western blot analysis. (C), NFκB-DNA binding activity. Nuclear extracts were prepared from tumor tissues derived 
from different treatment groups on week 6. NFκB-DNA binding activity was measured by Gelshift assay as described in Mate-
rials and Methods. The relative nuclear NFκB-DNA binding activities were quantified by scanning densitometry.








N






Control TRAIL Curcumin Curcumin + TRAIL











































&&'(!ț
	

)
ȕ

!

*
*
%




*





























(!ț








+%%%%%%%%%%%%%,%%%%%%%%%%%%%%%%%%%%%%%,+%%%%%%%%%%,+Molecular Cancer 2008, 7:16 http://www.molecular-cancer.com/content/7/1/16
Page 8 of 13
(page number not for citation purposes)
Our in vitro and in vivo studies demonstrate that curcumin
can engage cell-intrinsic pathway of apoptosis by regulat-
ing the expression of Bcl-2 family of proteins.
We and others have recently shown that curcumin caused
a growth arrest at G1/S stage in several cancers including
prostate [43-45]. The G1/S phase arrest by curcumin was
associated with the induction of p21/WAF1, p27/KIP1, and
p16, and inhibition of cyclin D1, cyclin E, Cdk4 and cdk
6 [45]. The ability of curcumin to induce cdk inhibitors
p21/CIP1 and p27/KIP1 and inhibit cyclin D1 expression was
also confirmed in our xenograft experiment. In a recent
study, we have demonstrated that inhibition of p21/CIP1
inhibited curcumin-induced cell cycle arrest and apopto-
sis [46]. We and others have also demonstrated that cur-
cumin induces the degradation of cyclin E expression
through ubiquitin-dependent pathway in several cancer
cell lines [44,45]. Interestingly, deregulated expression of
cyclin E correlated with chromosome instability [47],
malignant trasformation [48], tumor progression [49],
and patient survival [50]. Overall, our data suggest that
curcumin induces growth arrest at G1/S stage of cell cycle.
Entry of malignant cells into the vasculature (i.e. intrava-
sation) requires proteolytic remodeling of the extracellu-
lar matrix so that tumor cells may pass through the local
Effects of curcumin and/TRAIL on markers of angiogenesis Figure 6
Effects of curcumin and/TRAIL on markers of angiogenesis. (A), Immunohistochemistry was performed to measure the expres-
sion of VEGF in tumor tissues derived from control and treated mice on week 6. (B), Left panel, tumor tissue sections derived 
from control and treated mice on week 6 were stained with H & E and the number of blood vessels in ten field at 400 × mag-
nification were counted. Each column represents the mean ± SD. * or # = significantly different from control, P < 0.05. Middle 
panel, blood vessel quantification in tumors derived on week 6. Tumor sections from control and treated mice were stained 
with anti-CD31 antibody, and the number of CD31-positive blood vessels was counted. The results are shown as the mean ± 
SD. * or # = significantly different from control, P < 0.05. Right panel, tumor sections from control and treated mice obtained 
on week 6 were stained with anti-von Willebrand Factor (vWF) antibody to evaluate blood vessels. The results are shown as 
the mean ± SD. (C), VEGF receptor 2 (VEGF-R2)-positive circulating endothelial cells in mice on week 6. The blood cells from 
peripheral blood attached to the slide were stained with anti-VEGF-R2 antibody, and the number of positive cells was counted 
under a microscope. The results are shown as the mean ± SD. * or # = significantly different from control, P < 0.05. (D), 
Expression of VEGF and β-actin in tumor tissues derived on week 6 were measured by the Western blot analysis.
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stroma and penetrate the vessel wall. The circulatory sys-
tem then provides a means of transporting tumor cells to
distant sites where they extravasate and establish meta-
static lesions. Matrix metalloproteinase (MMP) is up-reg-
ulated in many tumor types and has been implicated in
tumor progression and metastasis. MMP is critical for
pericellular degradation of the extracellular matrix,
thereby promoting tumor cell invasion and dissemina-
tion. To grow efficiently in vivo, tumor cells induce angio-
genesis in both primary solid tumors and metastatic foci.
Our results showed that curcumin significantly inhibited
the growth of TRAIL-resistant LNCaP xenografts and sen-
sitized these xenografts to undergo apoptosis by TRAIL.
Tumor tissues derived from curcumin treated mice
showed that curcumin inhibibited proliferation (PCNA
and Ki67 staining), induced apoptosis (TUNEL staining),
metastasis (uPA, MMP-2 and MMP-9 staining), and ang-
iogenesis (CD31 and VEGF staining). Curcumin also
inhibited VEGFR2-positive circulating endothelial cells.
Treatment of LNCaP xenografted mice with TRAIL alone
had no effect on tumor growth, apoptosis, metastasis and
angiogenesis. Our recent in vitro studies demonstrated
that curcumin inhibits capillary tube formation and
endothelial cell migration, and the inhibitory effects of
curcumin were enhanced in the presence of ERK MAP
kinase inhibitor [35]. These data suggest that curcumin
can inhibit tumor growth by inhibiting apoptosis, metas-
tasis and angiogenesis.
TRAIL induces apoptosis in cancer cells which express
TRAIL-R1/DR4 and TRAIL-R2/DR5. We have shown that
the upregulation of death receptors by chemotherapeutic
drugs, irradiation and chemopreventive agents enhance or
sensitize cancer cells to TRAIL treatment [28,30,35,51-
58]. Specifically, TRAIL-resistant LNCaP cells can be sensi-
tized by chemotherapeutic drugs and irradiation in vitro
and in vivo through upregulation of death receptors DR4
and/or DR5 [27,28]. Similarly, our in vitro study has dem-
onstrated the upregulation of DR4 and DR5 in PC-3 and
LNCaP cells by curcumin [35]. Interestigly, curcumin sen-
Effects of curcumin and/TRAIL on markers of metastasis Figure 7
Effects of curcumin and/TRAIL on markers of metastasis. (A), Immunohistochemistry was performed to measure the expres-
sion of MMPs (MMP-2 and MMP-9) and uPA in tumor tissues derived from control and treated mice on week 6. (B), Expression 
of MMP-2, MMP-9, uPA and β-actin in tumor tissues derived on week 6 were measured by the Western blot analysis.
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sitized TRAIL-resistant LNCaP xenografts by inhibiting
tumor cell proliferation and inducing apoptosis which
were correlated with induction of death receptors DR4
and DR5. Death receptor (DR4 and/or DR5) regulation
has been shown to be under the control of transcription
factor NFκB, SP1 and p53 [59-64]. Inducible silencing of
KILLER/DR5  in vivo promoted bioluminescent colon
tumor xenograft growth and confers resistance to chemo-
therapeutic agent 5-fluorouracil [65]. These finding sug-
gest that upregulation of death receptors DR4 and DR5 by
curcumin may be one of the mechanisms by which curcu-
min enhances the therapeutic potnetial of TRAIL.
The NFκB family of transcription factors has been shown
to be constitutively activated in various human malignan-
cies, including a number of solid tumors, leukemias, and
lymphomas [66]. NFκB is shown to contribute to devel-
opment and/or progression of malignancy by regulating
the expression of genes involved in cell growth, differenti-
ation, apoptosis, angiogenesis and metastasis [66]. Pros-
tate cancer cells have been reported to have constitutive
NFκB activity due to increased activity of the IκB kinase
complex [67]. Furthermore, an inverse correlation
between androgen receptor (AR) status and NFκB activity
was observed in prostate cancer cell lines [68]. In prostate
cancer cells, NFκB may promote cell growth and prolifer-
ation by regulating expression of genes such as c-myc, cyc-
lin D1, and IL-6 [66,69], and inhibit apoptosis through
activation of expression of anti-apoptotic genes, such as
Bcl-2 and Bcl-XL. NFκB-mediated expression of genes,
involved in angiogenesis (IL-8, VEGF), invasion and
metastasis (MMP-9, uPA, uPA receptor), may further con-
tribute to the progression of prostate cancer. Constitutive
NFκB activity has also been demonstrated in primary
prostate cancer tissue samples and suggested to have prog-
nostic importance for a subset of primary tumors. In the
present study, curcumin inhibited the activation of NFκB
and its gene products such as VEGF, Bcl-2, Bcl-XL, uPA,
cyclin D1, MMP-2, MMP-9, COX-2 and IL-8 in LNCaP
xenografted tumors. These findings suggest that NFκB
may play a role in human prostate cancer development,
and/or progression, and curcumin can inhibit these proc-
esses through regulation of NFκB-regulated gene prod-
ucts.
Conclusion
Our in vivo experiments have demonstrated that curcumin
sensitizes TRAIL-resistant LNCaP cells through multiple
mechanisms. It induces death receptors, upregulates proa-
poptotic members of Bcl-2 family (Bax and Bak), inhibits
antiapoptotic Bcl-2 proteins (Bcl-2 and Bcl-XL) and mark-
ers of cell proliferation (PCNA and Ki67), and induces
expression of cell cycle inhibitors p21/CIP1, and p27/KIP1.
Furthermore, curcumin can also inhibit the activation of
NFκB and its gene products (e.g. VEGF, Bcl-2, Bcl-XL, uPA,
cyclin D1, MMP-2, MMP-9, COX-2 and IL-8) in vitro [35],
and in vivo (current study), which play significant roles in
invasion, metastasis and angiogenesis. All these events
will significantly contribute to the antiproliferative and
antitumor activities of curcumin. Clinical trials on curcu-
min have demonstrated that (1) curcuma extract can be
administered safely to patients at doses of up to 2.2 g
daily, equivalent to 180 mg of curcumin; and (2) curcu-
min has low oral bioavailability in humans and may
undergo intestinal metabolism [70]. Our studies posses
strong clinical potential because curcumin either alone or
in combination with TRAIL can be used to prevent and/or
treat prostate cancer.
Methods
Reagents
Antibodies against CD31, VEGF, VEGFR2, Bcl-2, Bcl-XL,
Bax, Bak, TRAIL-R1/DR4, TRAIL-R2/DR5 and β-actin were
purchased from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA). Antibodies against p21, p27, phospho-p65-
NFκB, Cox-2, IL-8, cyclin D1, uPA, MMP-2, and MMP-9
were purchased from Cell Signaling Technology, Inc.
(Danvers, MA). Enhanced chemiluminescence (ECL)
Western blot detection reagents were from Amersham Life
Sciences Inc. (Arlington Heights, IL). Terminal Deoxynu-
cleotidyl Transferase Biotin-dUTP Nick End Labeling
(TUNEL) assay kit was purchased from EMD Biosciences/
Calbiochem (San Diego, CA). TRAIL was purified as
described elsewhere [71]. Curcumin was purchased from
LKT Laboratories, Inc. (St. Paul, MN).
Western blot analysis
Western blot analysis was performed as we described ear-
lier [13]. Protein bands were visualized on X-ray film
using an enhanced chemiluminescence system.
Xenograft assays in nude mice
Athymic nude mice (Balb c nu/nu, 4–6 weeks old) were
purchased from the National Cancer Institute (Frederick,
MD). LNCaP cells (2 × 106cells as a 50% suspension in
matrigel, Becton Dickinson, Bedford, MA) in a final vol-
ume of 0.1 ml were injected subcutaneously at right flank
of Balb c nude mice. When the average tumor volume
reached about 100 mm3, mice were randomized into four
groups of 10 mice/group, and the following treatment
protocol was implemented: Group 1, vehicle control (0.1
ml normal saline containing 0.5 % DMSO) administered
by oral injection, three times/week (Monday, Wednesday
and Friday) beginning the day of tumor cell implantation
through out the duration of experiment; Group 2, TRAIL
(15 mg/kg) administered i.v. on day 1, 7, 14, and 21;
Group 3, curcumin (30 mg/kg, in 0.1 ml normal saline
containing 0.5 % DMSO) administered by oral injection,
three times/week (Monday, Wednesday and Friday)
beginning the day of tumor cell implantation through outMolecular Cancer 2008, 7:16 http://www.molecular-cancer.com/content/7/1/16
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the duration of experiment; Group 4, curcumin and TRAIL,
curcumin administered through oral injection, and TRAIL
administered i.v. Mice were housed under pathogen-free
conditions and maintained on a 12 h light/12 h dark
cycle, with food and water supplied ad libitum. Tumor vol-
ume was calculated using the equation: (volume = length
× width × depth × 0.5236 mm3). The in vivo experiment
was performed under IACUC's approved protocol.
Immunohistochemistry
Immunohistochemistry was performed as described ear-
lier (28, 29). In brief, tumor tissues were collected on
week 6, excised and fixed with 10% formalin, embedded
in paraffin and sectioned. Tissue sections were stained
with primary antibodies against Bax, Bak, Bcl-2, Bcl-XL,
DR4, DR5, Ki-67, PCNA, p21/WAF1/CIP1, p27/Kip1, IL-8,
Cox-2, phospho-p65-NFkB, CD31, VEGF, VEGFR2, MMP-
2, MMP-9 and uPA or TUNEL reaction mixture. For
immunohistochemistry, sections were fixed in cold 100%
acetone for 3 min, air-dried, and incubated with various
primary antibodies at room temperature for 4 h. Subse-
quently, slides were washed three times in PBS and incu-
bated with secondary antibody at room temperature for 1
h. Finally, alkaline phosphatase or hydrogen peroxide
polymer-AEC chromagen substrate kits were used as per
manufacturer' instructions (Lab Vision Corporation).
After washing with PBS, Vectashield (Vector Laboratories)
mounting medium was applied and sections were cover-
slipped and imaged.
Electrophoretic mobility shift assay
EMSA was performed as we described elsewhere [59].
Statistical analysis
The mean and SD were calculated for each experimental
group. Differences between groups were analyzed by one
or two way ANOVA. The non-parametric Mann-Whitney
U test was performed to assess the difference of tumor vol-
ume between control and treatment group. To assess the
difference between two groups under multiple condi-
tions, one-way ANOWA followed by Bonferoni's multiple
comparison tests were performed using PRISM statistical
analysis software (GrafPad Software, Inc., San Diego, CA).
Significant differences among groups were calculated at P
< 0.05.
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